US 8,629,111 B2
` Page 2
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2007/0015691 Al
`2007/0027072 Al
`2007/0087962 Al
`2007/0149447 Al
`2007/0299004 Al
`2008/0039378 Al
`2008/0070834 Al
`2008/0146497 Al
`2008/0207495 Al
`2009/0131307 Al
`2010/0279951 Al
`2011/0009339 Al
`2011/0294744 Al
`2012/0270805 Al
`2013/0059796 Al
`
`1/2007 Chang
`2/2007 Tien etal.
`4/2007 Tien et al.
`6/2007 Changet al.
`12/2007 Acheampongetal.
`2/2008 Graham etal.
`3/2008 Changet al.
`6/2008 Graham etal.
`8/2008 Graham etal.
`5/2009 Tien etal.
`11/2010 Morgan et al.
`1/2011 Schiffman
`12/2011 Morgan etal.
`10/2012 Changet al.
`3/2013 Changet al.
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`wo
`wo
`WO
`wo
`wo
`Wo
`wo
`wo
`
`1/1993
`3/1997
`11/1995
`1/2000
`§/2001
`6/2001
`2/2002
`6/2002
`4/2003
`7/2003
`
`0547229
`0760237
`95-31211
`00-00179
`01-32142
`01-41671
`02-09667
`02-49603
`03-030834
`03-053405
`
`9/1999 Kawashimaetal.
`5,951,971 A
`10/1999 Hauer et al.
`5,962,014 A
`10/1999 Hauer etal.
`5,962,017 A
`10/1999 Cho etal.
`5,962,019 A
`11/1999 Cavanak
`5,977,066 A
`11/1999 Ko etal.
`5,981,479 A
`11/1999 Dingetal.
`5,981,607 A
`12/1999 Sherman
`5,998,365 A
`12/1999 Friedman etal.
`6,004,566 A
`12/1999 Hauer etal.
`6,007,840 A
`12/1999 Singh
`6,008,191 A
`12/1999 Al-Razzak et al.
`6,008,192 A
`2/2000 Klokkersetal.
`6,022,852 A
`2/2000 Haueretal.
`6,024,978 A
`4/2000 Stuchlik etal.
`6,046,163 A
`5/2000 Mulye
`6,057,289 A
`12/2000 Sherman
`6,159,933 A
`3/2001 Sherman
`6,197,335 Bl
`7/2001 Garst
`6,254,860 Bl
`7/2001 Cho etal.
`6,254,885 Bl
`7/2001 Chen et al.
`6,267,985 Bl
`9/2001 Mishraetal.
`6,284,268 Bl
`9/2001 Patelet al.
`6,294,192 Bl
`10/2001 Cavanak
`6,306,825 Bl
`11/2001 Burke
`6,323,204 Bl
`OTHER PUBLICATIONS
`2/2002 Singhetal.
`6,346,511 Bl
`
`6,350,442 B2=2/2002 Garst Akpek, Esen Karamursel et al, A Randomized Trial of Topical
`6,413,547 Bl
`7/2002 Bennett et al.
`Cyclosporin
`0.05% in
`Topical
`Steroid-Resistant Atopic
`6,420,355 B2
`7/2002 Richteret al.
`K
`:
`oe
`6 468.968 B2
`10/2002. Cavanak et al.
`eratoconjunctivitis, Ophthalmology, 2004, 476-482, 111.
`6.475.519 Bl
`11/2002 Meinzeretal.
`Angelov, O. et al, Preclinical Safety Studies of Cyclosporine
`6,486,124 B2
`11/2002. Olbrich et al.
`Ophthalmic Emulsion, Adv Exp Med Biol, 1998, 991-995, 438.
`6,544,953 B2
`4/2003 Tsuzukiet al.
`Angelov, O. et al, Safety Assessment of Cyclosporine Ophthalmic
`6,555,526 B2
`4/2003 Matsuo
`Emulsionin Rabbits and Dogs, XIth Congress of the European Soci-
`6,562,873 B2
`5/2003 Olejnik et al.
`ety of Ophthalmology, 1997, 25-28, 1-5, Soc. Ophthalmol Eur., HU.
`6,569,463 B2
`5/2003 Patel et al.
`Ardizzone, Sandro et al, A Practical Guide to the Managementof
`6,582,718 B2
`6/2003 Kawashima
`Distal Ulcerative
`Colitis, D
`1998. 519-542. 55(4
`6,656,460 B2
`12/2003 Benita et al.
`istal
`Ulcerative Colitis,
`Drugs,
`1998,
`519-542,
`55(4).
`6,872,705 B2
`3/2005 Lyons
`Banic, Markoet al, Effect of Cyclosporine in a Murine Model of
`6,984,628 B2
`1/2006 Bakhit etal. 0.000000. 514/20.8
`Experimental Colitis, Digestive Diseases and Sciences, Jun. 2002,
`7,202,209 B2
`4/2007 Chang
`1362-1368, 47(6).
`7,276,476 B2
`10/2007 Chang etal.
`Bonini, S. et al, Vernal Keratoconjunctivitis, Eye, 2004, 345-351, 18.
`7,288,520 B2
`10/2007 Changet al.
`Brewster, Marcus et al, Enhanced Delivery of Ganciclovir to the
`FOLson BS
`l5008 aans
`Brain Through the Use of Redox Targeting, Antimicrobial Agents
`501,
`ien et al.
`8,211,855 B2
`7/2012 Chang etal.
`and Chemotherapy, Apr. 1994, 817-823, 38(4).
`8,288,348 B2
`10/2012 Changetal.
`Brewster, Marcusetal, Intravenous and Oral Pharmacokinetic Evalu-
`2001/0003589 Al
`6/2001 Neueret al.
`ation of a 2-Hydroxypropyl-B-cyclodextrin-Based Formulation of
`2001/0014665 Al
`8/2001 Fischeretal.
`Carbamazepine in the Dog: Comparison with Commercially Avail-
`2001/0036449 Al
`11/2001 Garst
`able Tablets and Suspensions, Journal of Pharmaceutical Sciences,
`2002/0012680 Al
`1/2002 Pateletal.
`Mar. 1997, 335-339, 86(3).
`.
`oe
`:
`2002/0013272 Al
`1/2002 Cavanak etal.
`B
`;
`rewster, Marcuset al, Preparation, Characterization, and Anesthetic
`2002/0016290 Al
`2/2002 Floc’h etal.
`:
`:
`
`2002/0016292 Al eniopenticsof 2-Hydroxypropyl-B-cyclodextrin Complexes|of2/2002. Richter et al.
`
`2002/0025927 Al
`9/2002 Olbrichetal.
`i Pregnanolonefand Pregnenolone in Rat and Mouse, Journal of Phar-
`2002/0045601 Al
`4/2002 Kawashima
`“HACeNICAPSciences, Oct. 1995, 1154-1159, 84(10).
`2002/0107183 Al
`8/2002 Petszulat et al.
`Brinkmeier, Thomaset al, Pyodermatitis-Pyostomatitis Vegetans: A
`2002/0119190 Al
`8/2002 Meinzeret al.
`Clinical Course of Two Decades with Response to Cyclosporine and.
`2002/0165134 Al
`11/2002 Richter etal.
`Low-Dose Prednisolone, Acta Derm Venereol, 2001, 134-136, 81.
`2003/0021816 Al
`1/2003 Kangetal.
`Castillo, Jose M. Benitez Delet al, Influence ofTopical Cyclosporine
`2003/0044452 Al
`3/2003 Ueno
`A and. Dissolvent on Corneal Epithelium Permeability of Fluores-
`2003/0055028 Al
`3/2003 Stergiopouloset al.
`cein, Documenta Ophthalmologica, 1995, 49-55, 91.
`2003/0059470 Al
`3/2003 Muller
`Cheeks,Lisaetal, Influence ofVehicle andAnterior ChamberProtein
`2003/0060402 Al
`3/2003 Cavanak et al.
`Cc
`trati
`Cyclosporine Penetration Through the Isolated.
`2003/0087813 Al
`5/2003. Oretal.
`oncenmation on
`SYCrosp
`3003/0104992 Al
`6/2003 Oret al.
`Rabbit Cornea, Current Eye Research, 1992, 641-649, 11(7).
`2003/0108626 Al
`6/2003 Benita etal.
`Database WPI Week 200044, Derwent Pub. Ltd., London, GB; An
`2003/0109425 Al
`6/2003 Oretal.
`2000-492678 & JP2000/143542, 2000, 2 Pages.
`2003/0109426 Al
`6/2003 Or et al.
`Ding, Shulin et al, Cyclosporine Ophthalmic O/W emulsion: Formu-
`2003/0133984 Al
`7/2003 Ambuhletal.
`lation and Emulsion Characterization, Pharm Res, 1997, 1 page, 14
`2003/0143250 Al
`7/2003 Hauer et al.
`(11).
`2003/0147954 Al
`8/2003 Yang etal.
`Donnenfeld, Eric D., The Economics ofUsing Restasis, Ophthalmol-
`2003/0166517 Al
`9/2003 Fricker etal.
`ogy Management, Oct. 2003, 3 pages, US.
`2005/0014691 Al
`1/2005 Bakhit etal.
`Drosos, A. A.et al, Efficacy and Safety of Cyclosporine-A Therapy
`2005/0059583 Al
`3/2005 Acheampong
`for Primary Sjogren’s Syndrome, Ter. Arkh., 1998, 77-80, 60(4).
`TEVA - EXHIBIT 1024 (PART 4 OF 4) 0503
`
`0503
`
`TEVA - EXHIBIT 1024 (PART 4 OF 4)
`
`

`

`US 8,629,111 B2
`
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Drosos, A.A. et al, Cyclosporin A Therapy in Patients with Primary
`Sjogren’s Syndrome: Results at One Year, Scand J Rheumatology,
`1986, 246-249, 61.
`Eisen, Drore et al, Topical Cyclosporine for Oral Mucosal Disorders,
`J Am Acad Dermatol, Dec. 1990, 1259-1264, 23.
`Epstein, Joeletal, Topical.Cxclesporine in a Bioadhesive for Treat-
`ment of Oral Lichenoid§MuscosalReactions, Oral Surg Oral Med
`Oral Pathol Oral, 1996, 532-536, 82.
`Erdmann,
`S.
`et
`al, Pemphigus Vulgaris Der Mund- Und
`Kehlkopfschleimhaut Pemphigus Vulgaris of the Oral Mucosa and
`the Larynx, H+G Zeitschrift Fuer Hautkrankheiten, 1997, 283-286,
`72(4).
`FDA Concludes Restasis (Cyclosporine) Not Effective for Dry Eye
`(Jun. 18, 1999). Accessed online at http://www.dryeyeinfo.org/
`Restasis_Cyclosporine.htm on Aug. 14, 2009. 1 Page.
`Gaeta, G.M. et al, Cyclosporin Bioadhesive Gel in the Topical Treat-
`ment of Erosive Oral Lichen Planus,
`International Journal of
`Immunopathology and Pharmacology, 1994, 125-132, 7(2).
`Gipson,Ilene et al, Character of Ocular Surface Mucins and Their
`Alteration in Dry Eye Disease, The Ocular Surface, Apr. 2004, 131-
`reeooemENY
`148, 2(2).
`Gremse, David et al, Ulcerative Colitis in ChildrenPediatr’Drugs,
`Sood
`2002, 807-815, 4(12).
`al, Topical Cyclosporin Treatment of
`Gunduz, Kaan
`et
`Keratoconjunctivitis Sicca in Secondary Sjogren’s Syndrome, Acta
`Ophthalmologica, 1994, 438-442, 72.
`http://web.archive.org/web/2001030625323/http://www.surfactant.
`co.kr/surfactants/pegester.html, 2001, 6 Pages, retrieved on Jul. 5,
`2008.
`Hunter, P.A. et al, Cyclosporin A Applied Topically to the Recipient
`Eye Inhibits Corneal Graft Rejection, Clin Exp Immunol, 1981,
`173-177, 45.
`Jumaa, Muhannadet al, Physicochemical Properties and Hemolytic
`Effect of Different Lipid Emulsion Formulations Using a Mixture of
`Emulsifiers, Pharmaceutica Acta Helvetiae, 1999, 293-301, 73.
`Kanai, A. et al, The Effect on the Cornea of Alpha Cyclodextrin
`Vehicle for Eye Drops, Transplantation Proceedings, Feb. 1989,
`3150-3152, vol. 21.
`Kanpolat, Ayfer et al, Penetration of Cyclosporin A into the Rabbit
`Cornea and Aqueous Humorafter Topical Drop and Collagen Shield
`Administration, Cornea/External Disease, Apr. 1994, 119-122,
`20(2) .
`yeeeaennmnnny
`Kaur, Rabinderet al, Solid Dispersions ofDrugs inPolyocyethylenet
`40 Stearate: Dissolution Rates and Physico-ChemicalInteractions,
`Journal of Pharmacy and Pharmacology, Dec. 1979, 48P.
`Kuwano, Mitsuaki et al, Cyclosporine A Formulation Affects Its
`Ocular Distribution in Rabbits, Pharmaceutical Research, Jan. 2002,
`108-111, 19(1).
`for
`Lambert Technologies Corp. Material Safety Data Sheet
`LUMULSE™POE-40 MSKP,last revision Aug. 22, 2003.3 pages.
`Leibovitz, Z. et al., Our Experience in Processing Maize (Corn) Germ
`Oil, Journal of the American Oil Chemists Society, Feb. 1983, 395-
`399, 80 (2), US.
`Lixin, Xie et al, Effect of Cyclosporine A Delivery System in Corneal
`Transplantation, Chinese Medical Journal, 2002, 110-113, 115 (1),
`US.
`Lopatin, D.E., Chemical Compositions and Functionsof Saliva, Aug.
`24, 2001, 31 Pages.
`Lyons, R.T.et al, Influence of Three Emulsion Formulation Param-
`eters on the Ocular Bioavailability of Cyclosporine A in Albino
`Rabbits, Am Assoc Pharm Sci, 2000, 1 Page, 2(4).
`Pedersen, Anne Marie et al, Primary Sjogren’s Syndrome: Oral
`Aspects on Pathogenesis, Diagnostic Criteria, Clinical Features and
`Approaches for Therapy, Expert Opin Pharma, 2001, 1415-1436,
`2(9).
`Phillips, Thomas et al, Cyclosporine Has a Direct Effect on the
`Differentiation of a Mucin-Secreting Cell Line, Journal of Cellular
`Physiology, 2000, 400-408, 184.
`
`Present, D.H. et al, Cyclosporine and Other Immunosuppressive
`Agents: Current and Future Role in the Treatment of Inflammatory
`Bowel Disease, American Journal of Gastroenterology, 1993, 627-
`630, 88(5).
`Restasis® Product Information Sheet, Allergan, Inc., 2009, 5 Pages.
`Restasis® Increasing Tear Production, Retrieved on Aug. 14, 2009,
`http://www.restasisprofessional.com/_clinical/clinical__increasing.
`htm 3 pages.
`Robinson, N. A. et al, Desquamative Gingivitis: A Sign of
`Mucocutaneous Disorders—a Review, Australian Dental Journal,
`2003, 205-211, 48(4).
`Rudinger,J., Characteristics of the Amino Acids as Components ofa
`Peptide Hormone Sequence, Peptide Hormones, 1976, 1-7.
`Sall, Kenneth et al, Two Multicenter, Randomized Studies of the
`Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Mod-
`erate to Severe Dry Eye Disease, Ophthalmology, 2000, 631-639,
`107.
`Sandborn, William et al, A Placebo-Controlled Trial of Cyclosporine
`Enemas for Mildly to Moderately Active Left-Sided Ulcerative
`Colitis, Gastroenterology, 1994, 1429-1435, 106.
`Sandborn, William et al, Cyclosporine Enemasfor Treatment-Resis-
`tant, Mildly to Moderately Active, Left-Sided Ulcerative Colitis,
`American Journal of Gastroenterology, 1993, 640-645, 88(5).
`Schwab, Matthias et al, Pharmacokinetic Considerationsin the Treat-
`ment of Inflammatory Bowel Disease, Clin Pharm, 2001, 723-751,
`60(10).
`Secchi, Antonio et al, Topical Use of Cyclosporine in the Treatment
`ofVernal Keratoconjunctivitis, American Journal of Ophthalmology,
`Dec. 1990, 641-645, 110.
`Small, Dave et al, The Ocular Pharmacokinetics of Cyclosporine in
`Albino Rabbits and Beagle Dogs, Ocular Drug Delivery and Metabo-
`lism, 1999, 54.
`Small, David et al, Blood Concentrations of Cyclosporin A During
`Long-Term Treatment With Cyclosporin A ophthalmic Emulsionsin
`Patients with Moderate to Severe Dry Eye Disease, Journal of Ocular
`Pharmacology and Therapeutics, 2002, 411-418, 18(5).
`Smilek, Dawnet al, A Single Amino Acid Change in a Myelin Basic
`Protein Peptide Confers the Capacity to Prevent Rather Than Induce
`Experimental Autoimmune Encephalomyelitis, Proc. Natl. Acad.
`Sci., Nov. 1991, 9633-9637, 88.
`Stephenson, Michelle, The Latest Uses of Restasis, Review of Oph-
`thalmology, Dec. 30, 2005, 7 Pages, US.
`Stevenson, Dara et al, Efficacy and Safety of Cyclosporin A
`ophthalmic Emulsion in the Treatment of Moderate-to-Severe Dry
`Eye Disease, Ophthalmology, 2000, 967-974, 107.
`Tesavibul, N.et al, Topical Cyclosporine A (CsA) for Ocular Surface
`Abnormalities
`in Graft Versus Host Disease Patients,
`Invest
`Ophthalmol Vis Sci, Feb. 1996, $1026, 37(3).
`The Online Medical Dictionary, Derivative, Analog, Analogue,
`Xerostomia, accessed Jul. 7, 2005 and Jul. 13, 2005, 6 Pages.
`Tibell, A. et al., Cyclosporin A in Fat Emulsion Carriers: Experimen-
`tal Studies on Pharmacokinetics and Tissue Distribution, Pharmacol-
`ogy & Toxicology, 1995, 115-121, 76, US.
`Tsubota, Kazuo et al, Use of Topical Cyclosporin A in a Primary
`Sjogren’s Syndrome Mouse Model, Invest OphthalmolVis Sci, Aug.
`1998, 1551-1559, 39(9).
`Van Der Reijden, Willy et al, Treatment of Oral Dryness Related
`Complaints (Xerostomia) in Sjogren’s Syndrome, Ann Rheum Dis,
`1999, 465-473, 58.
`Winter, T.A. et al, Cyclosporin A Retention Enemas in Refractory
`Distal Ulcerative Colitis and ‘Pouchitis’, Scand J Gastroenterol,
`1993, 701-704, 28.
`Pending U.S. Appl. No. 13/967,189, filed Aug. 14, 2013.
`Pending U.S. Appl. No. 13/976,179, filed Aug. 14, 2013.
`Pending U.S. Appl. No. 13/961,818, filed Aug. 7, 2013.
`Pending U.S. Appl. No. 13/961,835, filed Aug. 7, 2013.
`Pending U.S. Appl. No. 13/961,808, filed Aug. 7, 2013.
`Pending U.S. Appl. No. 13/961,828, filed Aug. 7, 2013.
`Pending U.S. Appl. No. 13/967,168, filed Aug. 14, 2013.
`Re-Exam U.S. Appl. No. 90/009,944, filed Aug. 27, 2011.
`
`* cited by examiner
`
`0504
`
`

`

`US 8,629,111 B2
`
`1
`METHODS OF PROVIDING THERAPEUTIC
`EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`RELATED APPLICATION
`
`This application is a continuation of copending U.S. appli-
`cation Ser. No. 13/961,828 filed Aug. 7, 2013, which is a
`continuation of copending U.S. application Ser. No. 11/897,
`177, filed Aug. 28, 2007, which is a continuation of U.S.
`application Ser. No. 10/927,857, filed Aug. 27, 2004, now
`abandoned, which claimed the benefit of U.S. Provisional
`Application No. 60/503,137 filed Sep. 15, 2003, which are
`incorporated in their entirety herein by reference.
`
`BACKGROUNDOF THE INVENTION
`
`The present invention relates to methods of providing
`desired therapeutic effects to humans or animals using com-
`positions including cyclosporin components. More particu-
`larly, the invention relates to methods including administer-
`ing to an eye of a humanor animala therapeutically effective
`amount of a cyclosporin component to provide a desired
`therapeutic effect, preferably a desired ophthalmic or ocular
`therapeutic effect.
`The use of cyclosporin-A and cyclosporin A derivatives to
`treat ophthalmic conditions has been the subject of various
`patents, for example Dinget al U.S. Pat. No. 5,474,979; Garst
`USS. Pat. No. 6,254,860; and Garst U.S. Pat. No. 6,350,442,
`this disclosure of each of whichis incorporatedin its entirely
`herein by reference.In addition, cyclosporin A compositions
`used in treating ophthalmic conditions is the subject of a
`number of publications. Such publicationsinclude,
`for
`example, “Blood concentrationsoficyclosporin a ‘during
`long-term treatment with!(cyclosporit*Spimaimie emul-
`sions in patients with mosPAETOSevERsdry eye disease,”
`Small etal, J Ocul Pharmacol Ther, 2002 October, 18(5):411-
`8; “Distribution of cyclosporin A in ocular tissues after topi-
`cal administration to albino rabbits and beagle dogs,”
`Acheamponget al, Curr Eye Res, 1999 February, 18(2):91-
`103b; “Cyclosporine distribution into the conjunctiva, cor-
`nea, lacrimal gland, and systemic blood following topical
`dosing of cyclosporine to rabbit, dog, and human eyes,”
`Acheamponget al, Adv Exp Med Biol, 1998, 438:1001-4;
`“Preclinical safety studies of cyclosporine ophthalmic emul-
`sion,’ Angelov et al, Adv Exp Med Biol, 1998, 438:991-5;
`“Cyclosporin & Emulsion & Eye,” Stevensonet al, Ophthal-
`mology, 2000 May, 107(5):967-74; and “Two multicenter,
`randomizedstudiesof the efficacy and safety of cyclosporine
`ophthalmic emulsion in moderate to severe dry eye disease.
`CsA Phase 3 Study Group,”Sall et al, Ophthalmology, 2000
`April, 107(4):631-9. Each of these publications is incorpo-
`rated in its entirety herein by reference.
`In addition,
`cyclosporin A-containing oil-in-water emulsions have been
`clinically tested, under conditions of confidentiality, since the
`mid 1990’s in order to obtain U.S. Food and Drug Adminis-
`tration (FDA) regulatory approval.
`Examples of useful cyclosporin A-containing emulsions
`are set out in Ding et al U.S. Pat. No. 5,474,979. Example 1 of
`this patent showsa series of emulsions in which the ratio of
`cyclosporin A to castor oil in each of these compositions was
`0.08 or greater, except for Composition B, which included
`0.2% by weight cyclosporin A and 5% by weight castor oil.
`The Dinget al patent placed no significance in Composition
`B relative to Compositions A, C and D of Example 1.
`Overtime, it has become apparentthat cyclosporinA emul-
`sions for ophthalmic use preferably have less than 0.2% by
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`65
`
`2
`weight of cyclosporin A. With cyclosporin A concentrations
`less than 0.2%, the amount of castor oil employed has been
`reduced since one of the functions of the castor oil is to
`
`solubilize the cyclosporin A. Thus, if reduced amounts of
`cyclosporin are employed, reduced amounts ofcastor oil are
`needed to provide effective solubilization of cyclosporin A.
`There continues to be a need for providing enhanced meth-
`ods of treating ophthalmic or ocular conditions with
`cyclosporin-containing emulsions.
`
`SUMMARYOF THE INVENTION
`
`New methods of treating a human or animal using
`cyclosporin component-containing emulsions have been dis-
`covered. Such methodsprovide substantialoverall efficacy in
`providing desired therapeutic effects.
`In addition, other
`important benefits are obtained employing the present meth-
`ods. For example, patient safety is enhanced.In particular,the
`present methods provide for reduced risks of side effects
`and/or drug interactions. Prescribing physicians advanta-
`geously have increased flexibility in prescribing such meth-
`ods and the compositions useful
`in such methods,
`for
`example, because of the reducedrisks of harmful side effects
`and/or drug interactions. The present methods can beeasily
`practiced. In short, the present methods provide substantial
`and acceptable overall efficacy, together with other advan-
`tages, such as increased safety and/orflexibility.
`In one aspect of the present invention, the present methods
`comprise administering to an eye of a human or animal a
`composition in the form of an emulsion comprising water, a
`hydrophobic component and a cyclosporin component in a
`therapeutically effective amountof less than 0.1% by weight
`of the composition. The weightratio of the cyclosporin com-
`ponent to the hydrophobic componentis less than 0.08.
`It has been foundthat the relatively increased amounts of
`hydrophobic componenttogether with relatively reduced, yet
`therapeutically effective, amounts of cyclosporin component
`provide substantial and advantageousbenefits. For example,
`the overall efficacy of the present compositions, for example
`in treating dry eye disease, is substantially equal to an iden-
`tical composition in which the cyclosporin componentis
`present in an amount of 0.1% by weight.Further, a relatively
`high concentration of hydrophobic componentis believed to
`provide for a more quick or rapid breaking downorresolving
`of the emulsion in the eye, which reduces vision distortion
`which may be caused bythe presence of the emulsion in the
`eye and/orfacilitates the therapeutic effectiveness ofthe com-
`position. Additionally, and importantly, using reduced
`amounts of the active cyclosporin component mitigates
`against undesirable side effects and/or potential drug interac-
`tions.
`In short, the present invention provides at least one advan-
`tageous benefit, and preferably a plurality of advantageous
`benefits.
`
`The present methods are useful in treating any suitable
`condition which is therapeutically sensitive to or treatable
`with cyclosporin components. Such conditionspreferably are
`ophthalmic or ocular conditions, that is relating to or having
`to do with one or moreparts of an eye of a humanor animal.
`Included among such conditions are, without limitation, dry
`eye syndrome, phacoanaphylactic endophthalmitis, uveitis,
`SSE SAAS
`vernal conjunctivitis, atopic)kerapoconjunctivitis,{corneal
`graft rejection andthe like conditions’The present invention
`is particularly effective in treating dry eye syndrome.
`Cyclosporin has been foundas effective in treating immune
`eto
`mediated keratoconjunctivitis sicca (KCSor dry eye disease).
`in a patient suffering therefrom. Theactivity oficyclosporine}
`Reexmmnnnnnrnnl
`
`0505
`
`0505
`
`

`

`“
`
`paneer
`_isasin immunosuppressant andinthe enhancementorrestor-
`‘ing of lacrimal glandtearing. Other conditions that can be
`treated with cyclosporin components include an absolute or
`partial deficiency in aqueoustear production (keratoconjunc-
`tivitis sicca, or KCS). Topical administration to a patient’s
`tear deficient eye can increase tear production in the eye. The
`treatment can further serve to correct corneal and conjuncti-
`val disorders exacerbated by tear deficiency and KCS, such as
`corneal scarring, cornealulceration,inflammationofthe cor-
`nea or conjunctiva, filamentary?keratisis, mucopurulent dis-
`charge andvascularization ofthevormes"
`Employing reduced concentrations of cyclosporin compo-
`nent, as in the present invention, is advantageously effective
`to provide the blood of the humanor animal undertreatment
`with reduced concentrations of cyclosporin component, pref-
`erably with substantially no detectable concentration of the
`cyclosporin component. The cyclosporin componentconcen-
`tration of blood can be advantageously measured using a
`validated liquid chromatography/mass spectrometry-mass
`spectrometry (VLC/MS-MS) analytical method, such as
`described elsewhere herein.
`In one embodiment,in the present methodstheblood ofthe
`human or animal has concentrations offclyclosporincompo-
`nent of 0.1 ng/mlorless.
`Sesmnssnennossnanannnnd
`Any suitable cyclosporin component effective in the
`present methods maybe used.
`Cyclosporins are a group of nonpolar cyclic oligopeptides
`with known immunosuppressant activity. Cyclosporin A,
`along with several other minor metabolites, cyclosporin B
`through I, have been identified. In addition, a number of
`synthetic analogs have been prepared.
`In general, commercially available cyclosporins may con-
`tain a mixture of several individual cyclosporins which all
`share a cyclic peptide structure consisting of eleven amino
`acid residues with a total molecular weight ofabout 1,200, but
`with different substituents or configurations of some of the
`amino acids.
`The term “cyclosporin component” as used herein is
`intendedto include any individual memberofthe cyclosporin
`group andderivatives thereof, as well as mixtures of two or
`more individual cyclosporins and derivatives thereof.
`Particularly preferred cyclosporin components include,
`without limitation, cyclosporin A, derivatives of cyclosporin
`A and the like and mixtures thereof. Cyclosporin A is an
`especially useful cyclosporin component.
`Anysuitable hydrophobic component may be employed in
`the present invention. Advantageously, the cyclosporin com-
`ponent is solubilized in the hydrophobic component. The
`hydrophobic component may be considered as comprising a
`discontinuous phase in the presently useful cyclosporin com-
`ponent-containing emulsions.
`The hydrophobic componentpreferably is present in the
`emulsion compositions in an amount greater than about
`0.625% by weight. For example, the hydrophobic component
`may be present in an amountofup to about 1.0% by weight or
`about 1.5% by weight or more of the composition.
`Preferably, the hydrophobic component comprises one or
`moreoily materials. Examples ofuseful oil materials include,
`without limitation, vegetable oils, animal oils, mineraloils,
`synthetic oils and the like and mixtures thereof. In a very
`useful embodiment, the hydrophobic component comprises
`one or more higherfatty acid glycerides. Excellent results are
`obtained when the hydrophobic component comprises castor
`oil.
`
`The presently useful compositions may include one or
`more other components in amounts effective to facilitate the
`usefulness and effectiveness of the compositions. Examples
`
`20
`
`25
`
`30
`
`40
`
`45
`
`50
`
`US 8,629,111 B2
`
`4
`of such other components include, without limitation, emul-
`sifier components,
`tonicity components, polyelectrolyte
`components, surfactant components, viscosity inducing com-
`ponents, acids and/or bases to adjust the pH of the composi-
`tion, buffer components, preservative components and the
`like. Components may be employed which are effective to
`perform two or more functionsin the presently useful com-
`positions. For example, components which are effective as
`both emulsifiers and surfactants may be employed, and/or
`components whichare effective as both polyelectrolyte com-
`ponents
`and viscosity inducing components may be
`employed. The specific composition chosen for use in the
`present
`invention advantageously is selected taking into
`account various factors present in the specific application at
`hand,
`for example,
`the desired therapeutic effect
`to be
`achieved, the desired properties of the compositions to be
`employed, the sensitivities of the human or animal to whom
`the composition is to be administered, and the like factors.
`The presently useful compositions advantageously are
`ophthalmically acceptable. A composition, component or
`material is ophthalmically acceptable whenit is compatible
`with ocular tissue, that is, it does not cause significant or
`undue detrimental effects when brought into contact with
`oculartissues.
`
`Such compositions have pH’s within the physiological
`range ofabout6 to about 10, preferably in a range ofabout 7.0
`to about 8.0 and more preferably in a range of about 7.2 to
`about 7.6.
`
`The present methodspreferably provide for an administer-
`ing step comprising topically administering the presently use-
`ful compositions to the eye or eyes of a humanor animal.
`Each and every feature described herein, and each and
`every combination of two or more of such features,
`is
`included within the scope of the present invention provided
`that the features included in such a combination are not mutu-
`ally inconsistent.
`These and other aspects and advantages of the present
`invention are apparent in the following detailed description,
`example and claims.
`
`DETAILED DESCRIPTION
`
`The present methodsare effective for treating an eye of a
`humanor animal. Such methods, in general, comprise admin-
`istering, preferably topically administering, to an eye of a
`humanor animal a cyclosporin component-containing emul-
`sion. The emulsion contains water, for example U.S. pure
`water, a hydrophobic component and a cyclosporin compo-
`nent ina therapeutically effective amountofless than 0.1% by
`weight of the emulsion. In addition, beneficial results have
`been found whenthe weightratio of the cyclosporin compo-
`nent to the hydrophobic componentis less than 0.08.
`As noted above, the present administering step preferably
`includes topically administering the emulsion to the eye of a
`patient of a human or animal. Such administering may
`involve a single use of the presently useful compositions, or
`repeated or periodic use of such compositions, for example,
`as required or desired to achieve the therapeutic effect to be
`obtained. The topical administration of the presently useful
`composition may involve providing the composition in the
`form of eye drops or similar form or other form so as to
`facilitate such topical administration.
`The present methods have been foundto be very effective
`in providing the desired therapeutic effect or effects while, at
`the same time, substantially reducing, or even substantially
`eliminating, side effects which mayresult from the presence
`of the cyclosporin componentin the blood of the human or
`
`0506
`
`0506
`
`

`

`US 8,629,111 B2
`
`5
`animalbeing treated, and eye irritation which,in the past, has
`been caused by the presence ofcertain componentsin priorart
`cyclosporin-containing emulsions. Also,
`the use of the
`present compositions which include reduced amounts of the
`cyclosporin components allow for more frequent administra-
`tion of the present compositions to achieve the desired thera-
`peutic effect or effects without substantially increasing the
`risk of side effects and/or eye irritation.
`The present methods are useful in treating any condition
`
`6
`copy (LC-MS/MS), whichtest has a cyclosporin component
`detection limit of 0.1 ng/ml. Cyclosporin component concen-
`trations below orless than 0.1 ng/ml are therefore considered
`substantially undetectable.
`The LC-MS/MStest is advantageously run as follows.
`One ml of blood is acidified with 0.2 ml of 0.1 N HCl
`
`solution, then extracted with 5 ml of methyl t-butyl] ether.
`After separation from the acidified aqueouslayer, the organic
`phase is neutralized with 2 ml of 0.1 N NaOH, evaporated,
`
`which is therapeutically sensitive to or treatable with 10 Yeconstituted in a water/acetonitrile-basedfnobilphase, and
`
`injected onto a 2.1x50 mm,3 um pore size C-8 reverse phase
`cyclosporin components. Such conditions preferably are oph-
`high pressure liquid chromatography (HPLC) column (Key-
`thalmic or ocular conditions, thatis relating to or having to do
`stone Scientific, Bellefonte, Pa.). Compoundsare gradient-
`with one or more parts of an eye of a human or animal.
`Included among such conditionsare, without limitation, dry ,, eluted at 0.2 mL/min and detected using an API III triple
`eye syndrome, phacoanaphylacticendophthalmitis,uveitis,
`quadrupole mass spectrometer with a turbo-ionspray source
`vernal conjunctivitis, atopic! kerapoconjunctivitis, \comeal
`(PE-Sciex, Concord, Ontario, Canada). Molecular reaction
`graft rejection andthe like conditions.Thepresentinvention
`monitoring enhances the sensitivity and selectivity of this
`is particularly effective in treating dry eye syndrome.
`assay. Protonated molecules for the analyte and an internal
`The frequency of administration and the amount of the 20 standard are collisionally dissociated and productions at m/z
`presently useful composition to use during each administra-
`425 are monitored for the analyte and the internal standard.
`tion varies depending upon the therapeutic effect
`to be
`Underthese conditions, cyclosporin A and the internal stan-
`obtained, the severity of the condition being treated and the
`dard cyclosporin G elute with retention times of about 3.8
`like factors. The presently useful compositions are designed
`minutes. The lower limit of quantitation is 0.1 ng/mL, at
`to allow the prescribing physician substantial flexibility in 25 which concentration thecoefficient ofvariation and deviation
`treating various ocular conditions to achieve the desired
`from nominal concentration is <15%.
`therapeutic effect or effects with reducedrisk of side effects
`Asnoted previously, any suitable cyclosporin component
`and/oreyeirritation. Such administration may occur on an as
`effective in the present methods may be employed. Very use-
`needed basis, for example, in treating or managing dry eye
`ful cyclosporin components include, without
`limitation,
`syndrome, on a one time basis or on a repeated or periodic 30 cyclosporin A, derivatives of cyclosporin A andthe like and
`basis once, twice, thrice or more times daily depending on the
`mixtures thereof.
`needs of the humanor animalbeingtreated and other factors
`The chemical structure for cyclosporin A is represented by
`involved in the application at hand.
`Formula 1
`
`Formula 1
`
`CH
`
`N~ 3
`
`oO
`
`N—CH;
`
`CH;
`
`H3C
`
`HO,,,
`
`CH;
`
`H;C
`H3C
`
`fs
`N
`
`QO
`
`3 Ny An
`
`CH;
`NH
`
`O
`
`0
`
`~
`WC”cH;
`
`CH
`
`oO
`
`°
`
`s
`Neu,
`
`O
`
`1C
`
`H;
`
`H;C
`
`CH;
`
`O
`
`CH;
`
`ye
`
`Asused herein the term “derivatives” ofa cyclosporin refer
`Oneof the important advantagesof the present invention is
`the reduced concentration of the cyclosporin component in © {o compounds having structures sufficiently similar to the
`the blood of the humanor animalas a result of administering
`cyclosporin so as to function in a mannersubstantially similar
`the present composition as described herein. One very useful
`to or substantially identical to the cyclosporin, for example,
`embodiment of the present administering step provides no
`cyclosporin A, in the present methods. Included, without
`substantial detectable concentration of cyclosporin compo-
`limitation, within the useful cyclosporin A derivatives are
`nent in the blood of the human or animal. Cyclosporin com-
`those selected from ((R)-methylthio-Sar)*-(4'-hydroxy-Me-
`ponent concentration in blood preferably is determined using
`Leu)
`cyclosporin A,
`((R)-(Cyclo)alkylthio-Sar)’-(4'-hy-
`a liquid chromatograp